<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/25/1-74-earnings-per-share-expected-for-albemarle-co-nysealb-this-quarter.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-25T21:30:48+00:00"/>
    <meta property="og:title" content="$1.74 Earnings Per Share Expected for Albemarle Co. (NYSE:ALB) This Quarter"/>
    <meta property="og:description" content="Wall Street brokerages expect Albemarle Co. (NYSE:ALB) to announce $1.74 earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Albemarle’s earnings, with the highest EPS estimate coming in at $1.81 and the lowest estimate coming in at $1.63. Albemarle reported earnings of $1.53 per share during […]"/>
  </head>
  <body>
    <article>
      <h1>$1.74 Earnings Per Share Expected for Albemarle Co. (NYSE:ALB) This Quarter</h1>
      <address><time datetime="2019-11-25T21:30:48+00:00">25 Nov 2019, 21:30</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/albemarle-corp-logo.gif"/>
      </figure>
      <p>Wall Street brokerages expect Albemarle Co. (NYSE:ALB) to announce $1.74 earnings per share for the current quarter, according to <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a>. Four analysts have made estimates for Albemarle’s earnings, with the highest EPS estimate coming in at $1.81 and the lowest estimate coming in at $1.63. Albemarle reported earnings of $1.53 per share during the same quarter last year, which would indicate a positive year over year growth rate of 13.7%. The firm is expected to announce its next quarterly earnings report on Wednesday, February 19th.</p>
      <p>According to Zacks, analysts expect that Albemarle will report full-year earnings of $6.08 per share for the current year, with EPS estimates ranging from $5.99 to $6.12. For the next year, analysts expect that the firm will report earnings of $4.83 per share, with EPS estimates ranging from $3.95 to $5.28. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Albemarle.</p>
      <p>Albemarle (NYSE:ALB) last posted its quarterly earnings data on Wednesday, November 6th. The specialty chemicals company reported $1.53 EPS for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.04. Albemarle had a return on equity of 15.94% and a net margin of 16.27%. The firm had revenue of $879.70 million for the quarter, compared to analyst estimates of $883.67 million. During the same quarter last year, the company earned $1.31 EPS. The company’s revenue was up 13.1% on a year-over-year basis.</p>
      <p>A number of research firms have commented on ALB. Morgan Stanley lowered their price objective on Albemarle from $60.00 to $50.00 and set an “underweight” rating on the stock in a research note on Friday. Wells Fargo &amp; Co lowered their price objective on Albemarle from $75.00 to $65.00 and set a “market perform” rating on the stock in a research note on Friday, October 25th. UBS Group lowered their price objective on Albemarle from $95.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, November 12th. BMO Capital Markets lowered their price objective on Albemarle from $95.00 to $80.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. They noted that the move was a valuation call. Finally, JPMorgan Chase &amp; Co. lowered Albemarle from a “neutral” rating to an “underweight” rating and decreased their price target for the company from $68.00 to $60.00 in a research note on Friday, November 8th. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. Albemarle has an average rating of “Hold” and an average target price of $83.26.</p>
      <p><a href="https://www.marketbeat.com/stocks/NYSE/ALB/earnings/">Albemarle stock</a> traded up $0.24 during mid-day trading on Monday, reaching $65.14. 1,090,698 shares of the company were exchanged, compared to its average volume of 1,501,245. The company has a fifty day simple moving average of $66.24 and a 200-day simple moving average of $67.94. Albemarle has a 12 month low of $58.63 and a 12 month high of $100.36. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.39 and a quick ratio of 0.82. The firm has a market cap of $6.91 billion, a PE ratio of 11.89, a PEG ratio of 1.09 and a beta of 1.63.</p>
      <p>The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 2nd. Stockholders of record on Friday, December 13th will be paid a $0.368 dividend. This is a positive change from Albemarle’s previous quarterly dividend of $0.37. The ex-dividend date of this dividend is Thursday, December 12th. This represents a $1.47 annualized dividend and a dividend yield of 2.26%. Albemarle’s dividend payout ratio (DPR) is presently 26.82%.</p>
      <p>In related news, CEO Luther C. Iv Kissam sold 36,000 shares of the business’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $70.00, for a total transaction of $2,520,000.00. Following the sale, the chief executive officer now owns 334,046 shares in the company, valued at approximately $23,383,220. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at <a href="https://www.sec.gov/Archives/edgar/data/915913/000091591319000084/xslF345X03/wf-form4_156875235326218.xml">this hyperlink</a>. Insiders own 1.02% of the company’s stock.</p>
      <p>A number of hedge funds have recently modified their holdings of ALB. Amundi Pioneer Asset Management Inc. grew its position in Albemarle by 0.3% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 176,692 shares of the specialty chemicals company’s stock worth $14,484,000 after acquiring an additional 460 shares during the last quarter. Bangor Savings Bank grew its position in Albemarle by 4.1% during the 2nd quarter. Bangor Savings Bank now owns 9,822 shares of the specialty chemicals company’s stock worth $692,000 after acquiring an additional 386 shares during the last quarter. KAMES CAPITAL plc grew its position in Albemarle by 13.8% during the 2nd quarter. KAMES CAPITAL plc now owns 543,705 shares of the specialty chemicals company’s stock worth $38,271,000 after acquiring an additional 65,865 shares during the last quarter. Retirement Systems of Alabama grew its position in Albemarle by 0.3% during the 2nd quarter. Retirement Systems of Alabama now owns 49,415 shares of the specialty chemicals company’s stock worth $3,479,000 after acquiring an additional 171 shares during the last quarter. Finally, SPX Equities Gestao de Recursos Ltda bought a new stake in Albemarle during the 2nd quarter worth $2,816,000. Institutional investors and hedge funds own 89.30% of the company’s stock.</p>
      <p>
        <b>Albemarle Company Profile</b>
      </p>
      <p>Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. Its Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and value-added lithium specialties, as well as reagents, such as butyllithium and lithium aluminum hydride for applications in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes, life science, pharmaceutical, and other markets.</p>
      <p>Recommended Story: <a href="https://www.marketbeat.com/financial-terms/what-is-a-dead-cat-bounce/">Dead Cat Bounce</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=ALB">Get a free copy of the Zacks research report on Albemarle (ALB)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=ALB"/>
      </figure>
    </article>
  </body>
</html>